ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs to address the unmet medical needs in central nervous system disorders. The company’s net income ratio is 0.36 reflecting its profitability margin. Despite the investment in research and development, the company reported selling, general, and administrative expenses of $548,894,000.00 indicating its operational overhead costs. The net total of other income and expenses is $34,093,000.00 reflecting non-core financial activities. Furthermore, the company incurred an income tax expense of -$252,096,000.00 indicating its tax obligations. The income before tax ratio is 0.13 reflecting the pre-tax margin. ACADIA offers NUPLAZID (pimavanserin) for treating hallucinations and delusions associated with Parkinson's disease psychosis, while its pipeline includes pimavanserin, currently under phase 3 development for Alzheimer's disease psychosis and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for Rett syndrome; ACP-044, an innovative first-in-class orally administered non-opioid analgesic under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, undergoing phase 1 development for schizophrenia and cognitive dysfunction in Alzheimer's. Founded in 1993, ACADIA is headquartered in San Diego, California. Currently, the stock is affordable at $24.42 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 1,589,854.00 indicating strong liquidity. With a mid-range market capitalization of $3,537,763,220.00 the company is regarded as a steady performer. ACADIA Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth in areas that address critical health challenges.